About Us

Board of Directors

Chris Adams, PhD, MBA
Founder and Chief Executive Officer

Chris Adams brings to Cydan more than 20 years of business development, transactional and commercial planning experience in orphan drug development as well as a successful track record in private and public biotech fund raising.

Prior to joining Cydan, Dr. Adams was President of CMA Biotech Consulting where he worked in an advisory role for a number of development stage orphan drug companies. Previously, Dr. Adams was Chief Business Officer of FoldRx Pharmaceuticals Inc., where he was responsible for business strategy, licensing and business development. He led the M&A process, which resulted in the acquisition of the company by Pfizer in October of 2010. Prior to FoldRx, Dr. Adams was Senior Vice President, Business Development for ViaCell Inc., and Vice President, Business Development for Transkaryotic Therapies Inc. Previously, Dr. Adams served Director of Business Development for the Pharmaceutical Division of Ciba-Geigy Limited, Basel, Switzerland.

Dr. Adams has a diploma in organic chemistry and biochemistry and a PhD in organic chemistry from the University of Zurich. Dr. Adams also holds an MBA from INSEAD of Fontainebleau, France.

Mette Kirstine Agger, MBA
Managing Partner, Lundbeckfond Ventures

Mette Kirstine has more than 20 years broad international experience within biotech / life science covering business development and licensing, management and financing. She was previously co-founder and CEO of 7TM Pharma A/S. She started her career as Patent Agent and has over the years co-founded several biotech companies. Mette has been appointed to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA.  Mette Kirstine is currently on the board of Veloxis, Allocure, PsiOxus, Harboe Breweries and Danish Staten Serum Institute.

Barbara J. Dalton, PhD
Vice President of Venture Capital, Pfizer Venture Investments

Barbara Dalton joined Pfizer in 2007 to manage the Pfizer Ventures Investments team within the Worldwide Business Development organization. She is responsible for growing their corporate venture activities, managing the corporation's private equity portfolio, advising on structured equity transactions and driving novel transactions to achieve corporate objectives. Dr. Dalton has more than 15 years of corporate venture capital experience in the pharmaceutical industry supporting and managing teams involved in direct and indirect health care investing. She has managed more than 30 fund investments and 80 diverse company investments in the U.S. and Europe and has had direct investing responsibility for biotechnology therapeutic and platform companies, as well as some healthcare IT and service businesses, including Alere, Ciphergen, Corixa, Genset, Gliatech, Gryphon, iJet, Lexicon, OGS, Third Wave and Rib-X Pharmaceuticals. In her current role, Dr. Dalton serves as the Chair of the Board for Celladon.

Dr. Dalton began her pharmaceutical career as a research scientist in immunology at SmithKline and French Laboratories and joined their venture capital group, SR One, Limited in the early 1990's. She was also a founding member and General Partner with EuclidSR Partners, a private venture capital firm, where SmithKline (now GSK) was a leading limited partner.

Dr. Dalton has also been supportive of the many regional and national organizations encouraging innovative startups in health care. She chaired her regional venture investors association, the MAC Alliance, and supported the venture philanthropy efforts of the Institute for the Study of Ageing as a Board member. She is an advisor to the Dean of the Eberly College of Science, where she received her undergraduate degree, and a member of The Penn State Research Foundation Board of Directors. She is on the Board of the New York Biotech Association, just stepped down from the Board of the National Venture Capital Association and she recently accepted the chairmanship of the health care sector of the New York City Investments Fund.

Dr. Dalton is a graduate of Penn State and received her PhD in microbiology and immunology from The Medical College of Pennsylvania (now the Drexel University College of Medical School).

Carl Goldfischer, MD
Investment Partner & Managing Director, Bay City Capital

Carl Goldfischer, MD, is an Investment Partner and Managing Director of Bay City Capital and has been with the firm since 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Previously, he was a Research Analyst with the Reliance Insurance Company, helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer serves on the board of directors of numerous companies, including: BrainCells, EnteroMedics, Epizyme, Metabolex and Poniard Pharmaceuticals. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College.

Joel S. Marcus, Board Observer
Chief Executive Officer & Founder, Alexandria Real Estate Equities, Inc.

Joel S. Marcus has served as Chairman of Alexandria Real Estate Equities’ Board of Directors since May 2007, Chief Executive Officer since March 1997, President since February 2009 and a Director since the Company’s inception in 1994. Mr. Marcus co-founded Alexandria Real Estate Equities, Inc. in 1994, Alexandria Venture Investments in 1996, and the annual Alexandria Summit in 2011.

Previously, Mr. Marcus was a partner at the law firm of Brobeck, Phleger & Harrison LLP, specializing in corporate finance and capital markets, venture capital and mergers and acquisitions. He also served as General Counsel and Secretary of Kirin-Amgen, Inc., a joint venture that financed the development of, and owned patents to, two multibillion dollar genetically engineered biopharmaceutical products. Mr. Marcus was formerly a practicing certified public accountant and tax manager with Arthur Young & Co. specializing in the financing and taxation of REITs.

Mr. Marcus serves on the Boards of the Accelerator Corporation, of which he was one of the original architects and co-founders, Foundation for the National Institutes of Health (FNIH), Intra-Cellular Therapies, Inc., Multiple Myeloma Research Foundation (MMRF) and the Partnership for New York City. Mr. Marcus received the Ernst & Young 1999 Entrepreneur of the Year Award (Los Angeles – Real Estate).

Mr. Marcus received his undergraduate and JD degrees from the University of California, Los Angeles.

David M. Mott, Chairman
General Partner, New Enterprise Associates

David Mott joined New Enterprise Associates (NEA) in September 2008 as a General Partner primarily focused on biopharmaceutical investments. Mr. Mott leads NEA’s healthcare investing practice, which typically comprises around 30 to 40 percent of each fund, or roughly $750 million to $1 billion of health care venture investment dollars every three to four years. The firm invests across all stages and geographies and is a leading investor across all health care sectors.

Prior to joining NEA, Mr. Mott was President and Chief Executive Officer of MedImmune, a subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. He joined MedImmune in 1992 and served in roles of increasing responsibility, including Chief Operating Officer, Chief Financial Officer, President and, from 2000, Chief Executive Officer as the company grew from a venture-backed startup (founded in 1988) into one of the top five biotechnology companies in the world. Ultimately, he initiated and executed the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. In 2002, Mr. Mott founded MedImmune Ventures and chaired its investment committee through his departure from MedImmune. At the time of his departure in July 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees.

Prior to joining MedImmune, Mr. Mott was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co. Inc, where he focused on public and private equity and debt financings as well as merger and acquisition work for biotechnology, health care services and medical product and device companies.

Mr. Mott is currently Chairman of Cydan, Mersana, 3-V Biosciences, TESARO and Zyngenia and is a director of Ardelyx, Epizyme, Omthera and Prosensa.

Sara Nayeem, MD, MBA
Partner, New Enterprise Associates

Sara Nayeem joined New Enterprise Associates’ (NEA) health care team in 2009 and focuses on investments in biopharmaceutical companies. In addition to Cydan, Dr. Nayeem serves on the Board of Mersana and as a Board Observer for Epizyme, Omthera, Tesaro and Zyngenia. She has also been involved in NEA’s investments in 3-V Biosciences and Prosensa and assists with the management of several of NEA's publicly traded portfolio companies.

Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration.

Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in biological sciences from Harvard University.